Science China-Life Sciences. 2021 May 27
Guoli Li, Bingqian Su, Pengfei Fu, Yilin Bai, Guangxu Ding, Dahua Li, Jiang Wang,Guoyu Yang, and Beibei
Products used in the paper Details Operation
LV-SpikenCoV- EGFP SARS-CoV-2 spike-bearing pseudovirus (LV-SpikenCoV- EGFP) was from PackGene Biotech (Guangzhou, China). Request Quote

Research Field: Covid-related

Keywords: broad-spectrum antiviral, NPC inhibition, CCP dynamics, viral entry


Viruses utilize cellular lipids and manipulate host lipid metabolism to ensure their replication and spread. Therefore, the identification of lipids and metabolic pathways that are suitable targets for antiviral development is crucial. Using a library of compounds targeting host lipid metabolic factors and testing them for their ability to block pseudorabies virus (PRV) and vesicular stomatitis virus (VSV) infection, we found that U18666A, a specific inhibitor of Niemann-Pick C1 (NPC1), is highly potent in suppressing the entry of diverse viruses including pseudotyped severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). NPC1 deficiency markedly attenuates viral growth by decreasing cholesterol abundance in the plasma membrane, thereby inhibiting the dynamics of clathrin-coated pits (CCPs), which are indispensable for clathrin-mediated endocytosis. Significantly, exogenous cholesterol can complement the dynamics of CCPs, leading to efficient viral entry and infectivity. Administration of U18666A improves the survival and pathology of PRV- and influenza A virus-infected mice. Thus, our studies demonstrate a unique mechanism by which NPC1 inhibition achieves broad antiviral activity, indicating a potential new therapeutic strategy against SARS-CoV-2, as well as other emerging viruses.

Popular Services

AAV Packaging Service

AAV Analytical Service

Vector Design